OUR SCIENCE

Amyotrophic Lateral Sclerosis (ALS)

ALS is a progressive motor neuron disease characterized by muscle weakness, paralysis, and respiratory failure. Most patients survive for 2–5 years after diagnosis. Existing treatments offer limited clinical benefit, and there is a significant unmet need. PhenoNet is developing treatments to slow disease progression and improve clinical outcomes.

Amyotrophic Lateral Sclerosis (ALS)

ALS is a progressive motor neuron disease characterized by muscle weakness, paralysis, and respiratory failure. Most patients survive for 2–5 years after diagnosis. Existing treatments offer limited clinical benefit, and there is a significant unmet need. PhenoNet is developing treatments to slow disease progression and improve clinical outcomes.

Most Prevalent 
Motor Neuron Disease

Our current clinical study targets early-stage patients with defined progression profiles, representing a more precise and promising approach to ALS drug development.


Roughly 90% of ALS cases are sporadic (sALS), with no known family history. The remaining 10% are familial ALS (fALS), usually inherited in an autosomal dominant pattern. ALS affects individuals of all ethnicities and races, though studies show a higher prevalence among Caucasians.


PHENOGENE-1A in Alzheimer Disease:


Mechanism of Action

Targets Aβ - amyloid monomer aggregation

Modulates neuroinflammatory pathways

Enhances synaptic and neurite function

Potential benefit in APOE4-negative gene carrier subgroups.

Most Prevalent Motor Neuron Disease

Our current clinical study targets early-stage patients with defined progression profiles, representing a more precise and promising approach to ALS drug development.


Roughly 90% of ALS cases are sporadic (sALS), with no known family history. The remaining 10% are familial ALS (fALS), usually inherited in an autosomal dominant pattern. ALS affects individuals of all ethnicities and races, though studies show a higher prevalence among Caucasians.


PHENOGENE-1A in Alzheimer Disease:



Mechanism of Action

Targets Aβ - amyloid monomer aggregation

Modulates neuroinflammatory pathways

Enhances synaptic and neurite function

Potential benefit in APOE4-negative gene carrier subgroups.


SHARE

PHENOGENE-1A in Alzheimer Disease:

Mechanism of Action


  • Targets Aβ - amyloid monomer aggregation
  • Modulates neuroinflammatory pathways
  • Enhances synaptic and neurite function
  • Potential benefit in APOE4-negative gene carrier subgroups.


This precision-medicine strategy may finally overcome the limitations of past trials by reducing patient heterogeneity and targeting upstream molecular mechanisms.



This precision-medicine strategy may overcome the limitations of past trials by reducing patient heterogeneity and targeting upstream molecular mechanisms.

SHARE